治疗晚期NSCLC的疫苗：Cimavax-EGF
Vaccine for the Treatment of Advanced NSCLC: Cimavax-EGF
DOI: 10.12677/ACM.2023.1392034, PDF,   
作者: 陈 卉：西安医学院研究生处，陕西 西安；张燕军*：陕西省肿瘤医院内三科主任，陕西 西安
关键词: 非小细胞肺癌；疫苗；Cimavax-EGF；免疫治疗；表皮生长因子(EGFR)；Non-Small Cell Lung Cancer； Vaccine； Cimavax-EGF； Immunotherapy； Epidermal Growth Factor (EGFR)
摘要: 现如今肺癌是发病率及死亡率较高的疾病，其中NSCLC占80%~85%。为提高患者的生存期及生存质量，免疫治疗及靶向治疗等发展的如火如荼。Cimavax-EGF作为一种治疗性的疫苗，前期临床试验已取得了喜人的结果，现已进入IV期临床试验阶段。本文旨在总结Cimavax-EGF与其他治疗晚期NSCLC药物联用后的效果及治疗进展。
Abstract: Nowadays, lung cancer is a disease with high morbidity and mortality, of which NSCLC accounts for 80%~85%. In order to improve the survival and quality of life of patients, the development of im-munotherapy and targeted therapy is in full swing. As a therapeutic vaccine, Cimavax-EGF has achieved gratifying results in pre-clinical trials and has now entered the phase IV clinical trial stage. This article aims to summarize the effect and treatment progress of Cimavax-EGF combined with other advanced NSCLC drugs.
文章引用：陈卉, 张燕军. 治疗晚期NSCLC的疫苗：Cimavax-EGF[J]. 临床医学进展, 2023, 13(9): 14548-14553. https://doi.org/10.12677/ACM.2023.1392034

参考文献

[1] International Agency for Research on Cancer (2014) Cancer Incidence in Five Continents Volume X (IARC, 2014).
[2] Shi, Y., Xing, P., Fan, Y., et al. (2015) Current Small Cell Lung Cancer Treatment in China. Thoracic Can-cer, 6, 233-238. [Google Scholar] [CrossRef] [PubMed]
[3] 赫捷, 魏文强. 2019中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2021: 145.
[4] Sardarabadi, P., Kojabad, A.A., Jafari, D. and Liu, C.H. (2021) Liquid Biop-sy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC). Biosen-sors (Basel), 11, Article No. 394. [Google Scholar] [CrossRef] [PubMed]
[5] Sun, Q., Li, W., Liu, T. and Guo, H. (2022) Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. Frontiers in Oncology, 12, Article ID: 916681. [Google Scholar] [CrossRef] [PubMed]
[6] Ryan, J. and Malinga, T. (2021) Interventions for Vaccine Hesitan-cy. Current Opinion in Immunology, 71, 89-91. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, Y., Shi, T., Song, X., Liu, B. and Wei, J. (2021) Gene Fusion Neoantigens: Emerging Targets for Cancer Immunotherapy. Cancer Letters, 506, 45-54. [Google Scholar] [CrossRef] [PubMed]
[8] Evans, R., Reid, M., Segal, B., Abrams, S.I. and Lee, K. (2018) Case Study in International Cooperation: Cuba’s Molecular Immunology Center and Roswell Park Cancer Institute. MEDICC Review, 20, 35-39. [Google Scholar] [CrossRef] 
[9] Rodríguez, P.C., Rodríguez, G., González, G. and Lage, A. (2010) Clinical Development and Perspectives of CIMAvax EGF, Cuban Vaccine for Non-Small-Cell Lung Cancer Therapy. MEDICC Review, 12, 17-23. [Google Scholar] [CrossRef] 
[10] Cheng, J.Y. and Kananathan, R. (2012) CIMAvax EGF Vaccine for Stage IIIb/IV Non-Small Cell Lung Carcinoma. Human Vaccines & Immunotherapeutics, 8, 1799-1801. [Google Scholar] [CrossRef] [PubMed]
[11] Ettinger, D.S., Wood, D.E., Aisner, D.L., Akerley, W., Bauman, J.R., Bha-rat, A., et al. (2021) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network, 19, 254-266. [Google Scholar] [CrossRef] [PubMed]
[12] 张佳颖, 朱磊, 杨宏宽, 等. CIMAvax-EGF在非小细胞肺癌中的治疗进展[J]. 中国医学科学院学报, 2018, 40(3): 411-414.
[13] Sellars, M.C., Wu, C.J. and Fritsch, E.F. (2022) Cancer Vaccines: Building a Bridge over Troubled Wa-ters. Cell, 185, 2770-2788. [Google Scholar] [CrossRef] [PubMed]
[14] Saavedra, D., Neninger, E., Rodriguez, C., Viada, C., Mazorra, Z., Lage, A. and Crombet, T. (2018) CIMAvax-EGF: Toward Long-Term Survival of Advanced NSCLC. Seminars in Oncology, 45, 34-40. [Google Scholar] [CrossRef] [PubMed]
[15] Castells Martínez, E.M., Del Valle, R., González, E.C., Melchor, A., Pérez, P.L., González, I., Carr, A. and León, K. (2017) An Enzyme Immunoassay for Determining Epider-mal Growth Factor (EGF) in Human Serum Samples Using an Ultramicroanalytical System. Journal of Immunoassay and Immunochemistry, 38, 190-201. [Google Scholar] [CrossRef] [PubMed]
[16] Crombet Ramos, T., Rodríguez, P.C., NeningerVinageras, E., Garcia Verdecia, B. and Lage Davila, A. (2015) CIMAvax EGF (EGF-P64K) Vaccine for the Treatment of Non-Small-Cell Lung Cancer. Expert Review of Vaccines, 14, 1303-1311. [Google Scholar] [CrossRef] [PubMed]
[17] Popa, X., García, B., Fuentes, K.P., Huerta, V., Alvarez, K., Viada, C.E., et al. (2020) Anti-EGF Antibodies as Surrogate Biomarkers of Clinical Efficacy in Stage IIIB/IV Non-Small-Cell Lung Cancer Patients Treated with an Optimized CIMAvax-EGF Vaccination Schedule. Oncoimmunol-ogy, 9, Article ID: 1762465. [Google Scholar] [CrossRef] 
[18] Rodriguez, P.C., Popa, X., Martínez, O., Mendoza, S., San-tiesteban, E., Crespo, T., et al. (2016) A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non- Small Cell Lung Cancer Patients. Clinical Cancer Research, 22, 3782-3790. [Google Scholar] [CrossRef] 
[19] Saavedra, D. and Crombet, T. (2017) CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Frontiers in Immunology, 8, Article No. 269. [Google Scholar] [CrossRef] [PubMed]
[20] Lorenzo-Luaces, P., Sanchez, L., Saavedra, D., Crombet, T., Van der Elst, W., Alonso, A., Molenberghs, G. and Lage, A. (2020) Identifying Predictive Biomarkers of CIMAvaxEGF Success in Non-Small Cell Lung Cancer Patients. BMC Cancer, 20, Article No. 772. [Google Scholar] [CrossRef] [PubMed]
[21] Tagliamento, M., Rijavec, E., Barletta, G., Biello, F., Rossi, G., Grossi, F. and Genova, C. (2018) CIMAvax-EGF, a Therapeutic Non-Small Cell Lung Cancer Vaccine. Expert Opinion on Biological Therapy, 18, 829-835. [Google Scholar] [CrossRef] [PubMed]
[22] Crombet Ramos, T., Santos Morales, O., Dy, G.K., León Monzón, K. and Lage Dávila, A. (2021) The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 11, Article ID: 639745. [Google Scholar] [CrossRef] [PubMed]
[23] Evans, R., Lee, K., Wallace, P.K., Reid, M., Muhitch, J., Dozier, A., et al. (2022) Augmenting Antibody Response to EGF-Depleting Immunotherapy: Findings from a Phase I Trial of CI-MAvax-EGF in Combination with Nivolumab in Advanced Stage NSCLC. Frontiers in Oncology, 12, Article ID: 958043. [Google Scholar] [CrossRef] [PubMed]
[24] Suárez, G.M., Catalá, M., Peña, Y., Portela, S., Añé-Kourí, A.L., González, A., et al. (2022) Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Dif-ferentiated EMRA T Cells in Advanced Lung Cancer Patients Treated with Platinum-Based Chemotherapy. Frontiers in Oncology, 12, Article ID: 823287. [Google Scholar] [CrossRef] [PubMed]
[25] Herrera, Z.M. and Ramos, T.C. (2014) Pilot Study of a Novel Combination of Two Therapeutic Vaccines in Advanced Non-Small-Cell Lung Cancer Patients. Cancer Immunology, Immunotherapy, 63, 737-747. [Google Scholar] [CrossRef] [PubMed]
[26] Sanchez, L., Muchene, L., Lorenzo-Luaces, P., Viada, C., Rodri-guez, P.C., Alfonso, S., Crombet, T., Neninger, E., Shkedy, Z. and Lage, A. (2018) Differential Effects of Two Thera-peutic Cancer Vaccines on Short- and Long-Term Survival Populations among Patients with Advanced Lung Cancer. Seminars in Oncology, 45, 52-57. [Google Scholar] [CrossRef] [PubMed]
[27] Flores Vega, Y.I., Páramo González, D.L., Alsina Sar-miento, S.C., AlsinaTul, L.E., Inguanzo Valdés, I.B., Rodríguez Machado, J., et al. (2023) Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario. Journal of Cancer, 14, 874-879. [Google Scholar] [CrossRef] [PubMed]
[28] Mancebo, A., Casacó, A., González, B., Ledón, N., Sorlozabal, J., León, A., et al. (2012) Repeated Dose Intramuscular Injection of the CIMAvax-EGF Vaccine in Sprague Dawley Rats Induces Local and Systemic Toxicity. Vaccine, 30, 3329-3338. [Google Scholar] [CrossRef] [PubMed]
[29] Fernández Lorente, A., Acosta Brooks, S., NeningerVinageras, E., Barroso Alvarez Mdel, C., Wilkinson Brito, B., Troche Concepción, M., et al. (2013) Effect of Blockade of the EGF System on Wound Healing in Patients Vaccinated with CIMAvax® EGF. World Journal of Surgical Oncology, 11, Arti-cle No. 275. [Google Scholar] [CrossRef] [PubMed]
[30] Rodriguez, P.C., Neninger, E., García, B., Popa, X., Viada, C., Luaces, P., et al. (2011) Safety, Immunogenicity and Preliminary Efficacy of Multiple-Site Vaccination with an Epidermal Growth Factor (EGF) Based Cancer Vaccine in Advanced Non Small Cell Lung Cancer (NSCLC) Patients. Journal of Immune Based Therapies and Vaccines, 9, Article No. 7. [Google Scholar] [CrossRef] [PubMed]

为你推荐